Smallpox primary prevention: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "{{Smallpox}} {{CMG}} ==Overview== ==References== {{reflist|2}} {{WH}} {{WS}} Category:Disease Category:Infectious disease Category:Pediatrics")
 
m (Changes made per Mahshid's request)
 
(78 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
{{Smallpox}}
{{Smallpox}}
{{CMG}}
{{CMG}}; {{AE}} {{JS}}


==Overview==
==Overview==
[[Primary prevention]] of [[smallpox]] consists in the administration of the ''vaccinia [[vaccine]]'', which attenuates or suppresses the manifestations of the disease, if administrated soon after [[infection]] has occurred. In the absence of an [[outbreak]], the [[vaccine]] is only administered to clinical and/or laboratory workers dealing with the [[smallpox virus|virus]] in specialized laboratories. It has several adverse effects, particularly in [[immunosuppressed]] individuals, those with [[heart]] conditions or [[allergies]], for whom its administration must be guided by specific rules.
==Primary Prevention==
The administration of the [[vaccine]] can attenuate, sometimes prevent, the manifestations of [[smallpox]]. The [[vaccine]] is made from a [[virus]] called vaccinia which is a “pox”-type [[virus]] related to [[smallpox]]. The [[vaccine]] does not contain the [[smallpox virus]] and therefore cannot transmit [[smallpox]]. However, it contains the “live” vaccinia [[virus]], not a dead [[virus]] like many others, for which the [[vaccination]] site must be cared for carefully, in order to prevent the [[virus]] from spreading.<ref name="BremanHenderson2002">{{cite journal|last1=Breman|first1=Joel G.|last2=Henderson|first2=D.A.|title=Diagnosis and Management of Smallpox|journal=New England Journal of Medicine|volume=346|issue=17|year=2002|pages=1300–1308|issn=0028-4793|doi=10.1056/NEJMra020025}}</ref> The [[vaccine]] is given in the upper arm, using a bifurcated needle, that is dipped into the [[vaccine]] solution. When removed, the needle retains a droplet of the [[vaccine]]. It is used to prick the [[skin]] a number of times in a few seconds. The pricking is not deep, reaching basilar [[epithelium]], but it will cause a sore spot and one or two droplets of [[blood]] will be formed.<ref name=CDC3>{{cite web | title = Emergence preparedness and response | url = http://www.bt.cdc.gov/agent/smallpox/vaccination/facts.asp }}</ref>
If the [[vaccination]] is successful, 1 or 2 droplets of [[blood]] will be formed within the site of the [[vaccine]], a few seconds after administration, and a [[cellular]] reaction will then occur. This will lead to the formation of the ''Jennerian pustule'' (1-2 cm), considered to be the ''major reaction''. The ''Jennerian pustule'' is a sign of successful [[vaccination]], which leads to full [[immunity]] in more than 95% of cases, possibly for 5 to 10 years.
Below is the progression of the appearance of the local of administrations of the [[vaccine]]: a red and [[itchy]] bump develops at the [[vaccine]] site within 3 to 4 days. During the first week, the bump becomes a large [[blister]], fills with [[pus]], and begins to drain. During the second week, the blister begins to dry up and a [[scab]] is formed. The scab then falls off during the third week, leaving a small [[scar]].<ref name=CDC3>{{cite web | title = Emergence preparedness and response | url = http://www.bt.cdc.gov/agent/smallpox/vaccination/facts.asp }}</ref>
[[Image:Smallpox vaccine.jpg|thumb|center|500px|<SMALL><SMALL>''[http://www.bt.cdc.gov/agent/smallpox/smallpox-images/vaxsit5a.htm  Adapted from Centers for Disease Control and Prevention (CDC), Centers for Disease Control and Prevention.]''<ref name="CDC">{{Cite web | title = Centers for Disease Control and Prevention (CDC) | url = http://www.bt.cdc.gov/agent/smallpox/smallpox-images/vaxsit5a.htm}}</ref></SMALL></SMALL>]]
People who were [[vaccinated]] prior to 1972, if revaccinated, may experience accelerated [[immune response]].
===Vaccine Generation===
Three generations of [[vaccines]] have been developed so far:
* ''1st generation'' - a mixture of related [[virus]]es, which differ from the remaining [[orthopoxvirus]]es. Reactions to these generation include:<ref name="BremanHenderson2002">{{cite journal|last1=Breman|first1=Joel G.|last2=Henderson|first2=D.A.|title=Diagnosis and Management of Smallpox|journal=New England Journal of Medicine|volume=346|issue=17|year=2002|pages=1300–1308|issn=0028-4793|doi=10.1056/NEJMra020025}}</ref><ref name="pmid13974310">{{cite journal| author=ROBERTS JA| title=Histopathogenesis of mousepox. I. Respiratory infection. | journal=Br J Exp Pathol | year= 1962 | volume= 43 | issue=  | pages= 451-61 | pmid=13974310 | doi= | pmc=PMC2095140 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13974310  }} </ref><ref name="MooreSeward2006">{{cite journal|last1=Moore|first1=Zack S|last2=Seward|first2=Jane F|last3=Lane|first3=J Michael|title=Smallpox|journal=The Lancet|volume=367|issue=9508|year=2006|pages=425–435|issn=01406736|doi=10.1016/S0140-6736(06)68143-9}}</ref>
:* [[Fever]]
:* Regional [[swelling]]
:* [[Edema]]
:* [[Headache]]
:* Painful [[lymphadenitis]]
* ''2nd generation'' - individual vaccinia clones, derived from [[virus]]es which are genetically similar, to the ones that made the 1st generation vaccine. This generation had a more efficient production of the [[vaccine]].<ref name="MooreSeward2006">{{cite journal|last1=Moore|first1=Zack S|last2=Seward|first2=Jane F|last3=Lane|first3=J Michael|title=Smallpox|journal=The Lancet|volume=367|issue=9508|year=2006|pages=425–435|issn=01406736|doi=10.1016/S0140-6736(06)68143-9}}</ref><ref name="pmid15014500">{{cite journal| author=Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH et al.| title=Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. | journal=Nature | year= 2004 | volume= 428 | issue= 6979 | pages= 182-5 | pmid=15014500 | doi=10.1038/nature02331 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15014500  }} </ref>
* ''3rd generation'' - developed from the attenuated vaccinia strains, after [[genetic]] manipulation or multiple passage through non-human tissue. Contains [[strains]] not as virulent as previous generations, and therefore safer, mainly because of a delay in replication of the [[virus]].<ref name="MooreSeward2006">{{cite journal|last1=Moore|first1=Zack S|last2=Seward|first2=Jane F|last3=Lane|first3=J Michael|title=Smallpox|journal=The Lancet|volume=367|issue=9508|year=2006|pages=425–435|issn=01406736|doi=10.1016/S0140-6736(06)68143-9}}</ref><ref name="pmid15014500">{{cite journal| author=Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH et al.| title=Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. | journal=Nature | year= 2004 | volume= 428 | issue= 6979 | pages= 182-5 | pmid=15014500 | doi=10.1038/nature02331 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15014500  }} </ref><ref name="pmid11395204">{{cite journal| author=Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG et al.| title=Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. | journal=Vaccine | year= 2001 | volume= 19 | issue= 27 | pages= 3700-9 | pmid=11395204 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11395204  }} </ref><ref name="pmid1566575">{{cite journal| author=Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI et al.| title=NYVAC: a highly attenuated strain of vaccinia virus. | journal=Virology | year= 1992 | volume= 188 | issue= 1 | pages= 217-32 | pmid=1566575 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1566575  }} </ref>
===Vaccine Recommendations===
Since [[smallpox]] was declared eradicated, [[vaccination]] is not advised for common citizens. The only people with formal indication for ''vaccinia vaccine'' are the laboratory or clinical individuals who work with the [[smallpox virus|virus]] at specialized laboratories.<ref name="BremanHenderson2002">{{cite journal|last1=Breman|first1=Joel G.|last2=Henderson|first2=D.A.|title=Diagnosis and Management of Smallpox|journal=New England Journal of Medicine|volume=346|issue=17|year=2002|pages=1300–1308|issn=0028-4793|doi=10.1056/NEJMra020025}}</ref>
===Vaccine Adverse Events===
The following adverse events to the [[vaccine]] have been reported:<ref name="MooreSeward2006">{{cite journal|last1=Moore|first1=Zack S|last2=Seward|first2=Jane F|last3=Lane|first3=J Michael|title=Smallpox|journal=The Lancet|volume=367|issue=9508|year=2006|pages=425–435|issn=01406736|doi=10.1016/S0140-6736(06)68143-9}}</ref><ref name="pmid12824210">{{cite journal| author=Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA et al.| title=Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. | journal=JAMA | year= 2003 | volume= 289 | issue= 24 | pages= 3283-9 | pmid=12824210 | doi=10.1001/jama.289.24.3283 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12824210  }} </ref><ref name="Arness2004">{{cite journal|last1=Arness|first1=M. K.|title=Myopericarditis following Smallpox Vaccination|journal=American Journal of Epidemiology|volume=160|issue=7|year=2004|pages=642–651|issn=0002-9262|doi=10.1093/aje/kwh269}}</ref><ref name="pmid14585633">{{cite journal| author=Chen RT, Lane JM| title=Myocarditis: the unexpected return of smallpox vaccine adverse events. | journal=Lancet | year= 2003 | volume= 362 | issue= 9393 | pages= 1345-6 | pmid=14585633 | doi=10.1016/S0140-6736(03)14674-0 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14585633  }} </ref>
* Fetal vaccinia
* Progressive vaccinia
* Generalized vaccinia
* Non-specific [[rashes]]
* [[Eczema vaccinatum]]
* [[Encephalitis]]
* [[Myopericarditis]]
===Vaccine Contraindications===
In the absence of reintroduction of [[smallpox]], [[vaccination]] is contraindicated in the following:<ref name="MooreSeward2006">{{cite journal|last1=Moore|first1=Zack S|last2=Seward|first2=Jane F|last3=Lane|first3=J Michael|title=Smallpox|journal=The Lancet|volume=367|issue=9508|year=2006|pages=425–435|issn=01406736|doi=10.1016/S0140-6736(06)68143-9}}</ref><ref name=CDC2>{{cite web | title = Recommendations for Using Smallpox Vaccine in a Pre-Event Vaccination Program
| url = http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5207a1.htm }}</ref>
* Patients with [[allergy]] to [[vaccine]] components
* History of [[atopic dermatitis]]
* History of exfoliative [[skin]] disorders
* [[Inflammatory]] eye disorders
* [[Immunosuppressed]] patients
* [[Heart disease]]
* [[Pregnancy]]
* Disease cases in the family
* Children <1 year
* [[Breastfeeding]]
====Post-Vaccination====
After [[vaccination]] it is important to follow instructions for the care of the [[vaccine]] site. Because the [[virus]] is alive, it can spread to other parts of the body, or to other people. The [[vaccinia virus]] may cause:<ref name=CDC3>{{cite web | title = Emergence preparedness and response | url = http://www.bt.cdc.gov/agent/smallpox/vaccination/facts.asp }}</ref>
* [[Rash]]
* [[Fever]]
* [[Headache]]
* [[Body]] pain
Elderly and pregnant women are prone to severe [[complications]] following the [[vaccinia virus]] vaccine.
====Vaccine Benefit====
[[Vaccination]] within 3 days of exposure will prevent or significantly lessen the severity of [[smallpox]] [[symptoms]] in the vast majority of people. [[Vaccination]] 4 to 7 days after exposure likely offers some protection from the disease or may modify its severity.<ref name=CDC3>{{cite web | title = Emergence preparedness and response | url = http://www.bt.cdc.gov/agent/smallpox/vaccination/facts.asp }}</ref>
===Vaccine===
The algorithm below demonstrates the action protocol in the presence of a patient who appears to show an adverse reaction to the [[smallpox]] vaccine.<ref name=CDC3>{{cite web | title = Emergence preparedness and response | url = http://www.bt.cdc.gov/agent/smallpox/vaccination/facts.asp }}</ref>
[[Image:Smallpox lab vaccine.jpg|thumb|center|800px|<SMALL><SMALL>''[http://emergency.cdc.gov/agent/smallpox/diagnosis/pdf/poxalgorithm5-2-14.pdf  Adapted from Laboratory Response Network (LRN [CDC]), Laboratory Response Network.]''<ref name="LRN(CDC)">{{Cite web | title = Public Health Image Library (PHIL), Centers for Disease Control and Prevention | url = http://emergency.cdc.gov/agent/smallpox/diagnosis/pdf/poxalgorithm5-2-14.pdf}}</ref></SMALL></SMALL>]]


==References==
==References==
{{reflist|2}}
{{Reflist|2}}
 
[[Category:Disease]]
 
[[Category:Pediatrics]]
[[Category:Smallpox]]
[[Category:Viral diseases]]
[[Category:Poxviruses]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Infectious disease]]
[[Category:Pediatrics]]

Latest revision as of 19:05, 18 September 2017

Smallpox Microchapters

Home

Patient Information

Overview

Historical Perspective

Eradication
Post-Eradication

Pathophysiology

Causes

Differentiating Smallpox from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Outbreak Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case Studies

Smallpox primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Smallpox primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Smallpox primary prevention

CDC on Smallpox primary prevention

Smallpox primary prevention in the news

Blogs on Smallpox primary prevention

Directions to Hospitals Treating Smallpox

Risk calculators and risk factors for Smallpox primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Primary prevention of smallpox consists in the administration of the vaccinia vaccine, which attenuates or suppresses the manifestations of the disease, if administrated soon after infection has occurred. In the absence of an outbreak, the vaccine is only administered to clinical and/or laboratory workers dealing with the virus in specialized laboratories. It has several adverse effects, particularly in immunosuppressed individuals, those with heart conditions or allergies, for whom its administration must be guided by specific rules.

Primary Prevention

The administration of the vaccine can attenuate, sometimes prevent, the manifestations of smallpox. The vaccine is made from a virus called vaccinia which is a “pox”-type virus related to smallpox. The vaccine does not contain the smallpox virus and therefore cannot transmit smallpox. However, it contains the “live” vaccinia virus, not a dead virus like many others, for which the vaccination site must be cared for carefully, in order to prevent the virus from spreading.[1] The vaccine is given in the upper arm, using a bifurcated needle, that is dipped into the vaccine solution. When removed, the needle retains a droplet of the vaccine. It is used to prick the skin a number of times in a few seconds. The pricking is not deep, reaching basilar epithelium, but it will cause a sore spot and one or two droplets of blood will be formed.[2]

If the vaccination is successful, 1 or 2 droplets of blood will be formed within the site of the vaccine, a few seconds after administration, and a cellular reaction will then occur. This will lead to the formation of the Jennerian pustule (1-2 cm), considered to be the major reaction. The Jennerian pustule is a sign of successful vaccination, which leads to full immunity in more than 95% of cases, possibly for 5 to 10 years.

Below is the progression of the appearance of the local of administrations of the vaccine: a red and itchy bump develops at the vaccine site within 3 to 4 days. During the first week, the bump becomes a large blister, fills with pus, and begins to drain. During the second week, the blister begins to dry up and a scab is formed. The scab then falls off during the third week, leaving a small scar.[2]

Adapted from Centers for Disease Control and Prevention (CDC), Centers for Disease Control and Prevention.[3]

People who were vaccinated prior to 1972, if revaccinated, may experience accelerated immune response.

Vaccine Generation

Three generations of vaccines have been developed so far:

  • 2nd generation - individual vaccinia clones, derived from viruses which are genetically similar, to the ones that made the 1st generation vaccine. This generation had a more efficient production of the vaccine.[5][6]
  • 3rd generation - developed from the attenuated vaccinia strains, after genetic manipulation or multiple passage through non-human tissue. Contains strains not as virulent as previous generations, and therefore safer, mainly because of a delay in replication of the virus.[5][6][7][8]

Vaccine Recommendations

Since smallpox was declared eradicated, vaccination is not advised for common citizens. The only people with formal indication for vaccinia vaccine are the laboratory or clinical individuals who work with the virus at specialized laboratories.[1]

Vaccine Adverse Events

The following adverse events to the vaccine have been reported:[5][9][10][11]

Vaccine Contraindications

In the absence of reintroduction of smallpox, vaccination is contraindicated in the following:[5][12]

Post-Vaccination

After vaccination it is important to follow instructions for the care of the vaccine site. Because the virus is alive, it can spread to other parts of the body, or to other people. The vaccinia virus may cause:[2]

Elderly and pregnant women are prone to severe complications following the vaccinia virus vaccine.

Vaccine Benefit

Vaccination within 3 days of exposure will prevent or significantly lessen the severity of smallpox symptoms in the vast majority of people. Vaccination 4 to 7 days after exposure likely offers some protection from the disease or may modify its severity.[2]

Vaccine

The algorithm below demonstrates the action protocol in the presence of a patient who appears to show an adverse reaction to the smallpox vaccine.[2]

Adapted from Laboratory Response Network (LRN [CDC), Laboratory Response Network.][13]

References

  1. ↑ 1.0 1.1 1.2 Breman, Joel G.; Henderson, D.A. (2002). "Diagnosis and Management of Smallpox". New England Journal of Medicine. 346 (17): 1300–1308. doi:10.1056/NEJMra020025. ISSN 0028-4793.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 "Emergence preparedness and response".
  3. ↑ "Centers for Disease Control and Prevention (CDC)".
  4. ↑ ROBERTS JA (1962). "Histopathogenesis of mousepox. I. Respiratory infection". Br J Exp Pathol. 43: 451–61. PMC 2095140. PMID 13974310.
  5. ↑ 5.0 5.1 5.2 5.3 5.4 Moore, Zack S; Seward, Jane F; Lane, J Michael (2006). "Smallpox". The Lancet. 367 (9508): 425–435. doi:10.1016/S0140-6736(06)68143-9. ISSN 0140-6736.
  6. ↑ 6.0 6.1 Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH; et al. (2004). "Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox". Nature. 428 (6979): 182–5. doi:10.1038/nature02331. PMID 15014500.
  7. ↑ Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG; et al. (2001). "Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques". Vaccine. 19 (27): 3700–9. PMID 11395204.
  8. ↑ Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI; et al. (1992). "NYVAC: a highly attenuated strain of vaccinia virus". Virology. 188 (1): 217–32. PMID 1566575.
  9. ↑ Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA; et al. (2003). "Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel". JAMA. 289 (24): 3283–9. doi:10.1001/jama.289.24.3283. PMID 12824210.
  10. ↑ Arness, M. K. (2004). "Myopericarditis following Smallpox Vaccination". American Journal of Epidemiology. 160 (7): 642–651. doi:10.1093/aje/kwh269. ISSN 0002-9262.
  11. ↑ Chen RT, Lane JM (2003). "Myocarditis: the unexpected return of smallpox vaccine adverse events". Lancet. 362 (9393): 1345–6. doi:10.1016/S0140-6736(03)14674-0. PMID 14585633.
  12. ↑ "Recommendations for Using Smallpox Vaccine in a Pre-Event Vaccination Program".
  13. ↑ "Public Health Image Library (PHIL), Centers for Disease Control and Prevention" (PDF).

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Smallpox_primary_prevention&oldid=1359547"